Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
- 5520 Nobel Drive, Suite 160
- Madison WI, 53711
- UNITED STATES
NanoOncology is a biotechnology company that was recently purchased by PeptiMed. Its mission is to identify specific tumor-causing genetic targets and designing small interfering RNA (siRNA)-based drugs and small molecules drugs that inhibit the tumor promoting function of gene products for each patient on an individual basis. The company invented EVIRNA ™, a proprietary siRNA therapeutic drug that targets the EVI1 gene for treatment of advanced breast, prostate, lung, colon, ovarian, and skin cancer. NanoOncology also invented a unique polypeptide-based nanoparticle system for delivery of siRNA directly to tumor cells.